Cargando…
Role of biologics in intractable urticaria
Chronic urticaria (CU) is a common condition faced by many clinicians. CU has been estimated to affect approximately 0.5%–1% of the population, with nearly 20% of sufferers remaining symptomatic 20 years after onset. Antihistamines are the first-line therapy for CU. Unfortunately, nearly half of the...
Autores principales: | Cooke, Andrew, Bulkhi, Adeeb, Casale, Thomas B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403603/ https://www.ncbi.nlm.nih.gov/pubmed/25926715 http://dx.doi.org/10.2147/BTT.S63839 |
Ejemplares similares
-
Effects of Exposure to New Car Interiors in Patients With Asthma and Allergic Rhinitis
por: Pepper, Amber N., et al.
Publicado: (2018) -
Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer
por: Hayama, Koremasa, et al.
Publicado: (2021) -
Biologic drugs in chronic spontaneous urticaria
por: Licari, Amelia, et al.
Publicado: (2021) -
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023) -
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
por: Sahota, Jagdeep, et al.
Publicado: (2018)